Identify High-Quality Drug Molecules Faster

Drug discovery requires a multidisciplinary approach. BIOVIA’s end-to-end integrated solutions for Small Molecule Therapeutics Design are built over 30 years of expertise in research informatics, physics-based molecular modeling and simulation, and lab informatics. They facilitate collaboration across multidisciplinary research teams to design, discover and develop small molecule drugs faster at reduced costs.

One Platform: Flexible, Scalable and Extensible Solutions on Cloud

BIOVIA's solutions for Small Molecule Therapeutics Design are available as Software-as-a-Service (SaaS) applications, seamlessly integrated on the 3DEXPERIENCE platform. They can accommodate the research needs of both small teams and large pharmaceutical organizations, allowing discovery teams to:

  • Easily deploy the newest solutions without hardware or IT investment
  • Customize data-driven workflows focused on unique requirements of individual research projects
  • Incorporate unique custom or third-party models, algorithms, and data sources.
Female scientists designing Small Molecule Therapeutics > Dassault Systemes
Two scientists discuss a small molecule therapeutic drug > Dassault Systemes

Highly Accurate Predictive Modeling with Active Learning Cycles

BIOVIA streamlines drug discovery by seamless integration of virtual lead identification and optimization methods with your own experimental design/testing in the lab. As a result, scientists can:

  • Make predictions on “what to make next” using “active learning”
  • Democratize access to predictive models for increased efficiency
  • Ensure data integrity, security, traceability, and consistency throughout the drug discovery lifecycle. 
     

State-of the-art Science with AI and Machine Learning

Reduce expensive real-world testing with generative AI

BIOVIA Generative Therapeutics Design (GTD) automates the virtual creation, testing and selection of novel small molecules with generative AI to design. It improves lead quality using multiparameter optimization (MPO) strategies that simultaneously address complex target product profiles (TPPs). Researchers use this intuitive AI-based workflow to shorten development timelines, discover obscured insights, explore chemical space and save millions of research dollars per program. GTD is the only commercial-grade software designed to empower computational and medicinal chemists with AI for small molecule drug development. 

Generative Therapeutics Design > Dassault Systemes

Harnessing the Power of AI-Ready Data

Gain Insights from Data

Make fast, informed decisions on which compounds to synthesize for testing.

With BIOVIA Insight, scientists can visualize, analyze, and browse molecular data proposed by Generative Therapeutics Design in detail, together with calculated properties and experimentally derived data, and can compare chemical structures, properties or other custom visualizations, while collaborating seamlessly with other team members.

BIOVIA Insight for SMTD > Dassault Systemes

Start Your Journey

The world of Small Molecule Therapeutics Design is changing. Discover how to stay a step ahead with BIOVIA

FAQ About Small Molecule Drugs

Learn What BIOVIA Can Do for You

Speak with a BIOVIA expert to learn how our solutions enable seamless collaboration and sustainable innovation at organizations of every size.

Get Started

Courses and classes are available for students, academia, professionals and companies. Find the right BIOVIA training for you. 

Get Help

Find information on software & hardware certification, software downloads, user documentation, support contact and services offering